Takashi Sekikawa

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 612 citations · Full text

Medicine, Endocrinology, Nephrology +10

Phenotypic Modulation of the Mesangium Reflected by Contractile Proteins in Diabetes

Hirofumi Makino, Naoki Kashihara, Hitoshi Sugiyama et al. · Diabetes · 1996 · 83 citations

Medicine, Cell Biology, Molecular Biology +16

Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial)

Katsuhiko Higuchi, Satoshi Tanabe, Ken Shimada et al. · European Journal of Cancer · 2014 · 82 citations

Medicine, Oncology, Pharmacology +11

S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial

Shuichi Hironaka, Naotoshi Sugimoto, Kensei Yamaguchi et al. · The Lancet Oncology · 2015 · 61 citations

Medicine, Oncology, Pharmacotherapy +10

Regulation of survival and death of mesangial cells by extracellular matrix

Hitoshi Sugiyama, Naoki Kashihara, Yohei Maeshima et al. · Kidney International · 1998 · 47 citations · Full text

Life Sciences, Cell Biology, Physiology +14